CFO
IONS icon

CVA Family Office’s Ionis Pharmaceuticals IONS Stock Holding History

CVA Family Office’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-30
Closed -$1.3K – 1292
2024
Q1 		$1.3K Hold
30
– – ﹤0.01% 977
2023
Q4 		$1.52K Buy
+30
New +$1.44K ﹤0.01% 934
2023
Q3 		– Sell
-30
Closed -$1.23K – 581
2023
Q2 		$1.23K Hold
30
– – ﹤0.01% 913
2023
Q1 		$1.07K Buy
+30
New +$1.13K ﹤0.01% 895

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

CVA Family Office's IONS Position: Q2 2024 in Review

CVA Family Office sold out of Ionis Pharmaceuticals (IONS) in Q2 2024, closing a stake of 30 shares — an estimated $1.3K sold.

CVA Family Office first reported a position in IONS in Q1 2023 and held it in 4 quarters. The position peaked at $1.52K in Q4 2023. 356 funds tracked by Wall St. Rank hold IONS as of Q2 2024.

  • CVA Family Office reported no remaining Ionis Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • CVA Family Office sold 30 Ionis Pharmaceuticals shares in Q2 2024, an estimated $1.3K.
  • CVA Family Office first reported a position in Ionis Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • CVA Family Office's Ionis Pharmaceuticals position peaked at $1.52K in Q4 2023.
  • 356 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2024.

Based on CVA Family Office's 13F filing for Q2 2024, filed 10 Jul 2024.